Endocrine Abstracts

Background: Vitamin D supplementation is an integral component of treating patients with osteoporosis/osteopenia. Data have shown that monthly vitamin D supplementation is not inferior to daily regarding target vitamin D levels. Moreover, it has been argued that monthly supplementation might increase adherence. Patients’ adherence and satisfaction with daily versus monthly vitamin D supplementation have been hardly investigated. The current study evaluated osteopenic/oste...

Background: Bisphosphonates are effective in malignancy-related hypercalcemia and have been beneficial in parathyroid-hormone (PTH)-dependent hypercalcemia in small randomized-controlled trials. However, data regarding efficacy and safety in PTH-dependent hypercalcemia is limited, and pamidronate is not indicated for this condition.Objective: To evaluate efficacy and safety of pamidronate in moderate-severe PTH-dependent hypercalcemia. Control groups wer...

Background: Denosumab (DMAb) and zoledronic acid (ZA) are potent, anti-resorptive agents used to treat patients with osteoporosis. It has been suggested that they increase parathyroid hormone (PTH) levels in response to their antiresorptive effect, and that PTH elevation might be responsible for DMAb modeling actions on bone. The timeline and magnitude of PTH elevation post-DMAb and ZA has not been characterized in a large patient population.Objective: T...